NASDAQ$REPL
Replimune Group Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fiscal fourth quarter and year ended March 31, 2021, and provided a business update.
Replimune reported its fiscal fourth-quarter and year-end 2021 financial results. The company is advancing its clinical programs and expects data updates in June. They ended the year with approximately $476 million in cash, which is expected to fund operations into the second half of 2024.
- Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC.
- Held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma.
- Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study.
- Ended fiscal year 2021 with approximately $476 million in Cash; Capitalized into second half of 2024.
Headline financials
Revenue & EPS history
Replimune · Revenue · Quarterly
$0
Forward guidance
Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+3.7%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+86.3%
Q4 2026
Best reaction
-11.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +86.3% | +114.2% | — | |
| Q3 2026 | +6.0% | +11.1% | +0.9% | |
| Q2 2026 | -0.8% | +6.4% | +23.7% | |
| Q1 2026 | -0.4% | -4.5% | +15.1% | |
| Q4 2025 | +3.9% | -0.5% | +9.6% | |
| Q3 2025 | +7.3% | +9.7% | -9.3% | |
| Q2 2025 | -6.5% | -13.6% | -2.2% | |
| Q1 2025 | +4.1% | +5.8% | +12.7% | |
| Q4 2024 | +1.5% | -11.5% | +24.7% | |
| Q3 2024 | +4.6% | -3.6% | +21.7% | |
| Q2 2024 | -10.3% | -13.7% | -40.9% | |
| Q1 2024 | -7.2% | -14.2% | -7.5% | |
| Q4 2023 | +0.4% | -0.2% | +22.3% | |
| Q3 2023 | -11.2% | -13.0% | -33.6% | |
| Q2 2023 | -3.5% | -6.1% | +5.8% | |
| Q1 2023 | +0.0% | -2.6% | -8.0% | |
| Q4 2022 | +3.9% | -0.6% | +6.8% | |
| Q3 2022 | -0.7% | +0.5% | -16.4% | |
| Q2 2022 | +0.9% | +0.2% | -16.6% | |
| Q1 2022 | -11.8% | -12.9% | -9.3% | |
| Q4 2021 | +5.7% | +5.8% | +3.3% | |
| Q3 2021 | +12.8% | +7.2% | -8.2% | |
| Q2 2021 | -1.6% | -6.2% | -1.1% | |
| Q1 2021 | +14.6% | +10.2% | +7.7% | |
| Q4 2020 | +17.8% | +19.5% | +11.0% | |
| Q3 2020 | -1.6% | -1.4% | -31.3% | |
| Q2 2020 | -1.3% | -27.9% | -12.5% | |
| Q1 2020 | -0.8% | +6.3% | +18.6% | |
| Q4 2019 | +1.4% | +1.4% | -5.7% | |
| Q3 2019 | +0.9% | -2.7% | -17.5% | |
| Q2 2019 | +0.7% | +8.9% | +7.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro